Whole Genome Sequencing is new tool for precision medicine in metastatic castration
resistant prostate cancer (mCRPC). This helps selecting patients who will get more benefit
with targeted therapy like PARP inhibitors.
• Such approach not only improves overall survival but also quality of life of patients and
chance of offering more number of subsequent line of therapy to prostate cancer patients
• In near future with precision medicine approach, we will be able to offer radio-ligand to
prostate cancer patients with PSMA expression, and immunotherapy to patients whose
tumor has microsatellite instability.
• Precision medicine has definite role in current management of CPRC.
Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
